Creo Medical's 'Speedboat Inject' used for first time in Europe

The AIM-traded firm said the procedure saw a seven-by-five centimetre cancerous lesion in the stomach removed in one piece in less than two hours.

It said it was performed after Dr Parra-Blanco led an upper GI endoscopy education and training day at the University of Nottingham, where familiarised himself with the Speedboat Inject device for use in the upper GI tract.

The result of the procedure was described as “excellent”, with the patient leaving hospital shortly after.

A second doctor was now also trained to use Speedboat Inject for upper GI procedures at Nottingham, and Nottingham University Hospital NHS Trust-led Upper GI ESD courses showcasing Speedboat were set to take place next week and in August at Queens Medical Centre in Nottingham.

Creo said it would continue to work closely with Nottingham University Hospital NHS Trust to support the training, mentoring and adoption of the device by numerous upper GI specialists over the coming months.

That, it said, would be in conjunction with Creo's Pioneer training programme, with the company expecting a rapid adoption of the device for upper GI procedures over the coming months.

“To have the first case completed at such a well-respected and prestigious endoscopic centre, renowned for its upper GI services, so soon after clearance demonstrates both the appetite for the device to be used in the upper GI tract in Europe and the ability for clinicians to quickly get optimal results once they are familiar with the advanced energy,” said chief executive officer Craig Gulliford.

“We look forward to continuing to work with Nottingham University Hospital NHS Trust and others to maximise the roll out of the device in the entire GI tract.”

At 1024 BST, shares in Creo Medical Group were up 9.06% at 36.7p.

Reporting by Josh White for Sharecast.com.